Immunogenicity, safety and reactogenicity of ROTAVAC® in healthy infants aged 6–8 weeks in Vietnam

ROTAVAC® is derived from human 116E rotavirus (RV) neonatal strain. In this study, we evaluated the immunogenicity, safety and reactogenicity of ROTAVAC® in Vietnam. We conducted a phase IV clinical trial in healthy infants aged 6–8 weeks using the complete regimen of ROTAVAC® with three doses. Seru...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2021-02, Vol.39 (7), p.1140-1147
Hauptverfasser:	Hai, Nguyen Minh, Dung, Nguyen Dang, Pho, Dinh Cong, Son, Vu Tung, Hoan, Vu Ngoc, Dan, Phan Tan, The Anh, Bui Dang, Giang, La Huong, Hung, Pham Ngoc
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Antibodies Antibodies, Viral Babies Biomedical research Clinical trials Cost estimates Demographics Enzyme-linked immunosorbent assay Fever Health care expenditures Humans Illnesses Immune response Immunogenicity Immunogenicity, Vaccine Immunoglobulin A Immunology Infant Infant, Newborn Infants Intussusception Neonates Parents & parenting ROTAVAC Rotavirus Rotavirus Infections - prevention & control Rotavirus Vaccines - adverse effects Safety Vaccination Vaccine Vaccines Vaccines, Attenuated Vietnam Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!